TY - JOUR
TI - Thalidomide in cancer medicine
AU - Eleutherakis-Papaiakovou, V
AU - Bamias, A
AU - Dimopoulos, MA
JO - Annals of Oncology
PY - 2004
VL - 15
TODO - 8
SP - 1151-1160
PB - Elsevier
SN - 0923-7534, 1569-8041
TODO - 10.1093/annonc/mdh300
TODO - angiogenesis; antiangiogenic therapy; cancer; myeloma; thalidomide
TODO - Thalidomide, an oral agent with antiangiogenic and immunomodulatory
properties, is being investigated extensively in the management of
advanced cancer. Multiple studies with large numbers of patients have
confirmed that this drug has significant activity in multiple myeloma.
Some patients with myelofibrosis or myeodysplatic syndromes may reduce
their need for transfusions after thalidomide treatment. The activity of
thalidomide in solid tumors is less prominent. Studies in Kaposi’s
sarcoma, malignant melanoma, renal cell carcinoma and prostate cancer
appear more promising especially when thalidomide is combined with
biological agents or with chemotherapy. Limited activity was
demonstrated in patients with glioma, while thalidomide appears to be
inactive in patients with head and neck cancer, breast or ovarian
cancer.
ER -